Trends in Pharmacological Sciences 1993: Vol 14 Index

14 Pages·1993·3.9 MB·English

Trends in
Dinarmacclosicall
SCIENCES essing oxs00:e0 seer
Subject Index
Author Index
Books Reviewed
1993
Vol 14
Issues 1—12
ISSN 0165 6147
Trends in Pharmacological Sciences
Elsevier Trends Journals
68 Hills Road
Cambridge
UK, CB2 ILA
Tel [phone]
Fax [phone]
Advisory Editorial Board E. J. Ariéns, Nijmegen, The Netherlands
P. M. Beart, Melbourne, Australia
N. J. M. Birdsall, London, UK
N. G. Bowery, London, UK
S. J. Cooper, Birmingham, UK
J. N. Crawley, Washington, USA
J. R. Fozard, Basel, Switzerland
B. Fredholm, Stockholm, Sweden
T. Godfraind, Belgium
J. W. Hadden, Tampa, FL, USA
J. Hughes, Cambridge, UK
L. Limbird, Nashville, TN, USA
J. Meldolesi, Milan, Italy
M. Otsuka, Tokyo, Japan
M. M. Reidenberg, New York, NY, USA
G. A. Robison, Houston, TX, USA
R. Ruffolo, Jr, King of Prussia, PA, USA
U. Schwabe, Heidelberg, Germany
F. J. E. Stefano, Buenos Aires, Argentina
H. Timmerman, Amsterdam, The Netherlands
M. Vore, Lexington, KT, USA
G. Zbinden, Zurich, Switzerland
Editor Debbie Girdlestone
Assistant Editor Rosie Perkins
Editorial Secretaries Belinda Holden and Anne Ward
© 1994 Elsevier Science Ltd
All rights reserved. No part of this publication may be translated, reproduced, stored in an electronic retrieval
system, published or transmitted, in any form or by any means, such as but not limited to, electronic, mechanical,
photocopying, recording or otherwise, without the prior written permission of the copyright owner and the
publisher, Elsevier Trends Journals, 68 Hills Road, Cambridge, UK CB2 1LA.
Author Index
BR Book Review
L_ Letter
SR Software Review
A Bonanno, G. and Raiteri, M., Multiple D
Adcock, I., see Barnes, P. J. 436 GABA, receptors 259 Davenport, A. P., see Haynes, W.G. — 225
Adorini, L., Guéry, J-C., Rodriquez- Botting, R.,s ee Salvemini, D. 36 Deakin, J. F. W., Graeff, F. G. and
Tarduchy, G. and Trembleau, S., Bradwejn, J., see Harro, J. 244 Guimaraes, F. S., Clinical implication of
Selective immunosuppression 178 Breckenridge, A. M., Lecture Notes on microdialysis findings, (L) 263
Ariéns, E. J., Nonchiral, homochiral and Clinical Pharmacology, 4th edn, (BR) Deakin, J. F. W., Graeff, F. G. and
composite chiral drugs 68 103 Guimaraes, F. S., Deakin et al. reply,
Arrigoni-Martelli, E., see Fritz, I. B. 355 Breckenridge, A. M., Pharmacology at a (L) 398
Artigas, F., 5-HT and antidepressants: new Glance, (BR) 103 Demetris, A. J., see Starzl, T. E. 217
views from microdialysis studies, Briley, M. and Moret, C., 5-HT and Dickenson, A. H., Pharmacology: Essentials
(L) 262 antidepressants: in vitro and in vivo of Basic Science, (BR) 105
Ashton, C. H., Inhibitors of Monoamine release studies, (L) 396 Dickenson, A. H., Pharmacology
Oxidase B, (BR) 384 Briley, M., Noradrenergic mechanisms in TextStack (SR) 105
Audibert, F. M. and Lise, L. D., Parkinson’s disease 33 Dijkstra, C. D., Polman, C. H. and
Adjuvants: current status, clinical Brines, R., see Gallagher, R. B. 137 Berkenbosch, F., Multiple sclerosis: some
perspectives and future Broder, S., see Yarchoan, R. 196 possible therapeutic opportunities 124
prospects 174 Brooker, G., see Cooper, D. M. F. 34 Dinarello, C. A., Modalities for reducing
Bruinvels, A., see Hibert, M. F. 7 interleukin-1 activity in disease 155
B Doble, A., 5-HT,, Agonists, 5-HT,
Bach, J-F., Immunosuppressive therapy of Cc Antagonists and Benzodiazepines:
autoimmune diseases 213 Caron, M. G., see Giros, B., 43 Their Comparative Behavioural
Bach, P. H. and Bartsch, H., Fungal toxins Carruthers, A. M. and Fozard, J. R., Pharmacology, (BR) 77
and health 424 Adenosine A, receptors: two into one Dougall, I. G., see Leff, P. 110
Barlow, R., Companion to Pharmacology, won't go 290 Dourish, C. T., see Fletcher, A. 441
(BR) 458 Caulfield, M. P., see Hall, J. M. 376 Dray, A. and Bevan, S., Inflammation and
Barlow, R. B., Effects of ‘rogue’ points on Cavalié, A., Electrophysiology: A Practical hyperalgesia: highlighting the team
non-linear fitting 399 Approach, (BR) 457 effort 287
Barlow, R. B., Gaddum revisited, (L) 296 Chandy, K. G. and Gutman, G. A., Du, X. Y., see Saxena, P. R., (L) 231
Barnes, P. J. and Adcock, I., Anti- Nomenclature for mammalian potassium Duggan, M. J., see Mills, A. 394
inflammatory actions of steroids: channel genes 434 Durieux, M. E. and Lynch, K. R., Signalling
molecular mechanisms 436 Chang, J. Y., see Glaser, K. B. 92 properties of lysophosphatidic acid 249
Bartsch, H., see Bach, P. H. 424 Chapman, R. W., Hey, J. A., Rizzo, C. A.
Bashir, Z. I. and Henley, J. M., The and Bolser, D. C., GABAg, receptors in E
French connection: a magnum of the lung 26 Eddie, L. W., see Kakouris, H. 4
excitatory amino acids in Christ, M., see Wehling, M. 1 Eddie, L. W., see Kakouris, H. (L) 232
Marseilles 387 Cliffe, I. A., see Fletcher, A. 441 Edenius, C., see Lindgren, J. A. 351
Bax, W. A., see Saxena, P. R., (L) 231 Cobbold, S., see Waldmann, H. 143 Edwards, G. and Weston, A. H., Ion
Beaumont, K., see Rink, T. J. 113 Coffman, R. L., see Powrie, F. 164 channels and their associated currents:
Beer, M. S., Middlemiss, D. N. and Collier, J. and Vallance, P., Investigations thoughts on a standardized
McAllister, G., 5-HT,-like receptors: six of vascular mechanisms: bridging the nomenclature 433
down and still counting 228 gap between basic research and clinical Ehrhardt, C., see Tapparelli, C. 366
Berkenbosch, F., see Dijkstra, C. D. 124 trials 257 Elliot, J., see Traynor, J. R. 84
Berry, M., see Logan, A. 337 Collis, M. G. and Hourani, S. M. O., Evans, R. H., Excitatory Amino Acid
Betz, H., Schuster, C., Ultsch, A. and Adenosine receptor subtypes 360 Receptors — Design of Agonists and
Schmitt, B., Molecular biology of Conn, P. J., see Schoepp, D. D. 13 Antagonists, (BR) 134
ionotropic glutamate receptors in Cook, N. S., see Tapparelli, C. 366
Drosophila melanogaster 428 Cook, N. S., see Tapparelli, C. 426 F
Bevan, S., see Dray, A. 287 Cooper, D. M. F. and Brooker, G., Ca?*- Ferrari, M. D. and Saxena, P. R., Clinical
Birdsall, N. J. M., see Lazareno, S. 237 inhibited adenylyl cyclase in cardiac and experimental effects of sumatriptan
Birkett, D. J., Mackenzie, P. I., Veronese, tissue 34 in humans 129
M. E. and Miners, J. O., In vitro Costa, T., see Lefkowitz, R. J. 303 Fletcher, A., Cliffe, I. A. and Dourish, C. T.,
approaches can predict human drug Cotecchia, S., see Lefkowitz, R. J. 303 Silent 5-HT,, receptor antagonists: utility
metabolism 292 Cox, D. A. and Matlib, M. A., as research tools and therapeutic agents
Bittiger, H., Froestl, W., Mickel, S. J. and Modulation of intramitochondrial free 441
Olpe, H-R., re i Se antagonists: Ca** concentration by antagonists of Forsythe, I. D., Jon Channels, Vol. 3,
from synthesis to therapeutic Na*-Ca?* exchange 408 (BR) 385
applications 391 Craig, D. A., The Cheng—Prusoff Fozard, J. R., see Carruthers, A. M. 290
Boddeke, H. W. G. M., see Hoyer,D. — 270 relationship: something lost in the Fredholm, B. B., Caffeine, Coffee and Health,
(BR) 454
Bolser, D. C., see Chapman, R. W. 26 translation 89
ili
Fritz, I. B. and Arrigoni-Martelli, E., Sites of 5-HT receptors 233 Metternich, R, see Tapparelli, C. 426
action of carnitine and its derivatives on Huxtable, R. J., Rhubarb: The Wondrous Mickel, S. J., see Bittiger, H. 391
the cardiovascular system: interactions Drug, (BR) 75 Middlemiss, D. N., Brain Biochemistry and
with membranes 355 Huxtable, R. J., Adverse Effects of Herbal Brain Disorders, (BR) 77
Froestl, W., see Bittiger, H. 39] Drugs, (BR) 75 Middlemiss, D. N., see Beer, M. S. 228
Fuller, R. W., Microdialysis studies with Huxtable, R. J., American Health Quackery, Mikoshiba, K., Inositol 1,4,5-triphosphate
5-HT reuptake inhibitors, (L) 397 (BR) 134 receptor 86
Miller, R. C., Pelton, J. T. and Huggins,
G I J. P., Endothelins — from receptors to
Galione, A., Inositol Phosphates and Calcium Illes, P. and Norenberg, W., Neuronal medicine 54
Signalling. Advances in Second Messenger ATP receptors and their mechanisms Milligan, G., Agonist regulation of cellular
and Phosphoprotein Research, Vol. 26, of action 50 G protein levels and distribution:
(BR) 78 mechanisms and functional
Gallagher, R. B., Brines, R. and J | implications 413
Girdlestone, D., Why Jenkinson, D. H., Potassium Channel Milligan, G., Mechanisms of
immunopharmacology? 137 Modulators, (BR) 255 multifunctional signalling by G
Gerzer, R., see Wehling, M. l protein-linked receptors 239
Girdlestone, D., see Gallagher, R. B. 137 K Mills, A. and Duggan, M. J., Orphan
Giros, B. and Caron, M. G., Molecular Kakouris, H., Eddie, L.W . and Summers, seven transmembrane domain
characterization of the dopamine R. J., Kakouris et al. reply, (L) 232 receptors: reversing
transporter 43 Kakouris, H., see Eddie, W. and Summers, pharmacology 394
Glaser, K. B., Mobilio, D., Chang, J. Y. and R. J., Relaxin: more than just a hormone Miners, J. O., see Birkett, D. J. 292
Senko, N., Phospholipase A, enzymes: of pregnancy 4 Misu, Y. and Goshima, Y., Is L-dopa an
their regulation and inhibition 92 Kaufman, D.L. and Tobin, A. J., endogenous neurotransmitter? 119
Goldie, R. G., see Hay, D. W. P. 29 Glutamate decarboxylases and Mitsuya, H., see Yarchoan, R. 196
Goshima, Y., see Misu, Y. 119 autoimmunity in insulin-dependent Mobilio, D., see Glaser, K. B. 92
Graeff, F. G., see Deakin, J. F. W. (L) 263 diabetes 107 Montastruc, J-L., see Senard, J-M. 349
Graeff, F. G., see Deakin, J. F. W. (L) 398 Kemp, J. A. and Leeson, P. D., The glycine Moret, C., see Briley, M. (L) 396
Grahame-Smith, D. G., Clinical site of the NMDA receptor — five years Morgan, P. H., Agonist action
Pharmacology. Seventh edition, (BR) 104 on 20 revisited 421
Greenshaw, A. J., Behavioural Kenakin, T. P., Synoptic receptor function, Morley, J., Immunopharmacology of
pharmacology of 5-HT, receptor (L) 431 asthma 208
antagonists: a critical update on Kishimoto, T., see Hadden, J. 138 Morley, J., New approaches to asthma
therapeutic potential 265 Koda, J., see Rink, T. J. 113 therapy, (L) 432
Guard, S., see Hall, J. M. 376 Krause, J. E., see Watling, K. J. 81 Murase, N. , see Starzl, T. E. 217
Guéry, J-C., see Adorini, L. 178
Guimaraes, F. S., see Deakin, J. F. W. L N
(L) 263 Lanius, R. A., Pasqualotto, B. A. and Shaw, Nahorski, S. R., see Wojcikiewicz,
Guimaraes, F. S., see Deakin, J. F. W. C. A., Age-dependent expression, R.J.H. 279
(L) 398 phosphorylation and function of Navia, M. A. and Peattie, D. A., Structure-
Gutman, G. A., see Chandy, K. G. 434 neurotransmitter receptors: based drug design: applications in
pharmacological implications 403 immunopharmacology and
H Lazareno, S. and Birdsall, N. J. M., immunosuppression 189
Hadden, J. W., Immunostimulants 169 Alternatives to the use of the Nichols, C. G., The ‘inner core’ of inwardly
Hadden, J.W. and Kishimoto, T., Cheng-Prusoff equation 237 rectifying K+ channels 320
Introduction to immunopharmacology Leeson, P. D., see Kemp, J. A. 20 Norenberg, W., see Illes, P. 50
138 Leff, P. and Dougall, I. G., Further
Hagan, R. M. and McLean, S., Vineyard concerns over Cheng-Prusoff analysis O
peptide conference bears fruit 315 110 Olpe, H-R., see Bittiger, H. 391
Hall, J. M., Caulfield, M. P., Watson, S. P. Lefkowitz, R. J., Cotecchia, S., Samama, P. Ottenheijm, H. C. J., see Van Geerestein,
and Guard, S., Receptor subtypes or and Costa, T., Constitutive activity of V. J., (BR) 133
species homologues: relevance to drug receptors coupled to guanine
discovery 376 nucleotide regulatory proteins 303 P
Harris, W. J., see Winter, G. 139 Lindgren, J. A. and Edenius, C., Pardoll, D. M., Cancer vaccines 202
Harro, J., Vasar, E. and Bradwejn, J., CCK Transcellular biosynthesis of Pardridge, W. M., An Introduction to the
in animal and human research on leukotrienes and lipoxins via leukotriene Blood—Brain Barrier, (BR) 313
anxiety 244 A, transfer 351 Parsons, M.E., see Pope, A. J. 323
Hartig, P., see Humphrey, P. P. A. 233 Lise, L. D., see Audibert, F. M. 174 Pasqualotto, B. A., see Lanius, R. A. 403
Hay, D. W. P., Henry, P. J. and Goldie, Liu, J., FK506 and ciclosporin A: molecular Pears, C., Protein kinase C: Current Concepts
R. G., Endothelin and the respiratory probes for studying mechanisms of and Future Perspectives, (BR) 286
system 29 intracellular signal transduction 182 Peattie, D. A., see Navia, M. A. 189
Haynes, W. G., Davenport, A. P. and Livett, B. G., Chromaffin cells: roles for Pelton, J. T., see Miller, R. C. 54
Webb, D. J., Endothelin: progress in vesicle proteins and Ca?* in hormone Polman, C. H. , see Dijkstra, C. D. 124
pharmacology and physiology 225 secretion and exocytosis 345 Pongs, O., Potassium channel
Henley, J. M., see Bashir, Z. I. 387 Logan, A. and Berry, M., Transforming nomenclature: a personal view 435
Henry, P., see Hay, D. W. P. 29 growth factor-B, and basic fibroblast Poole, A., Fluorescent and Luminescent
Hey, J. A., see Chapman, R. W. 26 growth factor in the injured CNS 337 Probes for Biological Activity, (BR) 456
Hibert, M. F., Trumpp-Kallmeyer, S., Lukas, S. E., Current perspectives on Pope, A. J. and Parsons, M.E., Reversible
Hoflack, J. and Bruinvels, A., This is not anabolic—androgenic steroid abuse _ 61 inhibitors of the gastric H*/Kt-
a G protein-coupled receptor 7 Lynch, K. R., see Durieux, M. E. 249 transporting ATPase: a new class of
Hoflack, J. , see Hibert, M. F. 7 antisecretory agent 323
Hourani, S. M. O., see Collis, M. G. 360 M Powrie, F. and Coffman, R. L., Cytokine
Hoyer, D. and Boddeke, H. W. G. M., MacIntyre, I., New perspectives in regulation of T-cell function: potential
Partial agonists, full agonists, osteoporosis 319 for therapeutic intervention 164
antagonists: dilemmas of definition 270 Mackenzie, P. I., see Birkett, D. J. 292 Preziosi, P., Animal Models in Toxicology,
Hoyer, D., see Humphrey, P. P. A. 233 Mann, J., Drugs from Natural Products, (BR) 254
Huggins, J. P., see Miller, R. C. 54 (BR) 455
Hughes, J., Murder, Magic and Medicine, Matlib, M. A., see Cox, D. A. 408 Q
(BR) 314
McAllister, G., see Beer, M. S. 228 Quast, U., Do the K+ channel openers relax
Humphrey, P. P. A., Hartig, P. and Hoyer, McLean, S., see Hagan, R. M. 315 smooth muscle by opening K* channels?
D., A proposed new nomenclature for Metternich, R., see Tapparelli, C. 366 332
R why? 98 Veal, J. M., Nucleic Acid Targeted Drug
Raiteri, M., see Bonanno, G. 259 Spedding, M. and Vanhoutte, P. M., Design, (BR) 385
Reith, M.E.A., see Wiener, H. L., (L) 294 Channel nomenclature: [UPHAR Veronese, M. E., see Birkett, D. J. 292
Ricordi, C., see Starzl, T. E. 217 recommendations 435 Vitetta, E. S., Thorpe, P. E. and Uhr, J. W.,
Rink, T. J., Beaumont, K., Koda, J. and Starzl, T. E., Demetris, A. J., Murase, N., Immunotoxins: magic bullets or
Young, A., Structure and biology of Thomson, A. W., Trucco, M. and Ricordi, misguided missiles? 148
amylin 113 C., Donor cell chimerism permitted by Volpe, P., see Sorrentino, V. 98
Rizzo, C. A., see Chapman, R. W. 26 immunosuppressive drugs: a new view
Rodriquez-Tarduchy, G., see Adorini, L. of organ transplantation 217 Ww
178 Stewart, A. G., Tomlinson, P. R. and Waldmann, H. and Cobbold, S., The
Rogawski, M. A., Therapeutic potential of Wilson, J., Airway wall remodelling in use of monoclonal antibodies
excitatory amino acid antagonists: asthma: a novel target for the to achieve immunological
channel blockers and 2,3- development of anti-asthma drugs 275 tolerance 143
benzodiazepines 325 Summers, R. J., see Kakouris, H. 4 Waldmann, T. A., The IL-2/IL-2 receptor
Summers, R. J., see Kakouris, H., (L) 232 system: a target for rational immune
S Swillens, S., Swillens replies, (L) 295 intervention 159
Salvemini, D. and Botting, R., Modulation Warrander, A., Drug Toxicokinetics,
of platelet function by free radicals and T (BR) 419
free-radical scavengers 36 Tapparelli, C., Metternich, R. and Cook, Watling, K. J. and Krause, J. E., The rising
Samama, P., see Lefkowitz, R. J. 303 N. S., Structure and function of thrombin sun shines on substance P and related
Saunders, J., The Design of Drugs to receptors 426 peptides 81
Macromolecular Targets, (BR) 135 Tapparelli, C., Metternich, R., Ehrhardt, C. Watson, S. P., see Hall, J. M. 376
Saxena, P. R., Cerebral Blood Flow and and Cook, N. S., Synthetic low-molecular Webb, D. J. , see Haynes, W. G. 225
Metabolism, (BR) 285 weight thrombin inhibitors: molecular Wehling, M., Christ, M. and Gerzer, R.,
Saxena, P. R., Bax, W. A., Du, X. Y. and design and pharmacological profile 366 Aldosterone-specific membrane
Schoemaker, R. G., Cardiac effects of Thomson, A. W., see Starzl, T. E. 217 receptors and related rapid, non-
relaxin, (L) 231 Thorpe, P. E., see Vitetta, E. S. 148 genomic effects |
Saxena, P. R., see Ferrari, M. D. 129 Tobin, A. B., see Wojcikiewicz, R.J. H. 279 Wess, J., Molecular basis of muscarinic
Schmitt, B., see Betz, H. 428 Tobin, A. J., see Kaufman, D.L. , 107 acetylcholine receptor function 308
Schoemaker, R. G., see Saxena, P. R., Tomlinson, P. R., see Stewart, A. G. 275 Weston, A. H., see Edwards, G. 433
(L) 231 Traynor, J. R. and Elliot, J., d~Opioid Wiener, H. L. and Reith, M.E.A.,
Schoepp, D. D. and Conn, P. J., receptor subtypes and cross-talk with Unknown radioligand specific
Metabotropic glutamate receptors in L-receptors 84 activity, (L) 294
brain function and pathology 13 Trembleau, S., see Adorini, L. 178 Wilson, J., see Stewart, A. G. 275
Schuster, C., see Betz, H. 428 Trucco, M., see Starzl, T. E. 217 Winkler, H., Hermann Blaschko
Seeburg, P. H., The TiPS/ TINS Lecture: Trumpp-Kallmeyer, S., see Hibert, M. F. (1900-1993) 264
The molecular biology of mammalian 7 Winter, G. and Harris, W. J., Humanized
glutamate receptor channels 297 antibodies 139
Senard, J-M. and Montastruc, J-L., U Wojcikiewicz, R. J. H., Tobin, A. B. and
Adrenoceptor regulation in orthostatic Uhr, J. W., see Vitetta, E. S. 148 Nahorski, S. R., Desensitization of cell
hypotension during autonomic failure Ultsch, A., see Betz, H. 428 signalling mediated by
349 phosphoinositidase C 279
Senko, N., see Glaser, K. B. 92 Vv Woodman, O. L., see Sobey, C. G. 448
Shaw, C. A., see Lanius, R. A. 403 Vallance, P., see Collier, J. 257
Sobey, C. G. and Woodman, O. L., Van Geerestein, V. J. and Ottenheijm, Y
Myocardial ischaemia: what happens to H. C. J., Atlas of Protein Side-Chain Yarchoan, R., Mitsuya, H. and Broder, S.,
the coronary arteries? 448 Interactions, Volumes I and II, (BR) 133 Challenges in the therapy of HIV
Sorrentino, V. and Volpe, P., Ryanodine Vanhoutte, P. M., see Spedding, M. 435 infection 196
receptors: how many, where and Vasar, E., see Harro, J. 244 Young, A., see Rink, T. J. 113

Subject Index
compiled by Angela Thorne
Acetylcholine receptors, see muscarinic and alum 175 and 5-HT, receptor antagonists 268
nicotinic acetylcholine receptors Alzheimer’s disease 366, 446 paradoxical drug effects 406
acid secretion amine transport and transporter proteins 47
inhibition 323 and chromaffin cells 346 antiemetics 265
1s,3R-ACPD, see 1-aminocyclopentane-1,3- amino acids, critical antiflammins 95
dicarboxylic acid in constitutive receptor activity 305 antigens 143, 202, 213, 220
acquired immune deficiency syndrome in FK506-binding protein 186 antigen-presenting cells 143, 178, 204, 221
(AIDS) 171, 196 in G protein-coupled receptors 7 antinociception 84, 265
acute and chronic myelogenous in HIV 199 antioxidants 36
leukemia 157 in ionotropic glutamate receptors 298 antipsychotics 267
acylcarnitine derivatives 355 in K* channel proteins 322 antisense oligonucleotides 200, 278
adenosine A, receptor 34, 360, 382 in muscarinic acetylcholine receptors 309 anti-Tac antibody 140, 159
adenosine A, receptors 290, 364 in tachykinin receptors 380 antitumour vaccines 202, 253
adenosine receptors in thrombin receptors 370, 426 anxiety 244, 445
subtypes 360 1-amino-4-phosphonobutanoic acid anxiolytics 77 (BR), 244, 266, 445
adenylyl cyclase 34, 241, 421 (AP4) 15 AP-1 (transcription factor) 438
(see also named receptors) 2-amino-3-phosphonopropionic acid AP3, see 2-amino-3-phosphonopropionic acid
adjuvants 169, 174, 204 (AP3) 14 AP4, see 1-amino-4-phosphonobutanoic acid
a-adrenoceptors 1-aminocyclopentane-1,3-dicarboxylic acid 3-APPi, see 3-aminopropylphosphinic acid
in autonomic failure 349 (1s, 3R-ACPD) 13, 389 arachidonic acid 92, 352
cloned subtypes 423 3-aminopropylphosphinic acid argatroban 372
and multifunctional signalling 242 (3-APPi) 26, 261, 391 aromatic amino acid decarboxylase
mutants 304 AMPA receptors 297, 329, 387 (AADC) 119
and Parkinson's disease 34 amphetamine 43 arteries
species homologues 381 amylin 113, 319 mechanisms in 257
B-adrenoceptors amylin receptors 115 and myocardial ischaemia 448
desensitization 282 anabolic—androgenic steroids 61 and sumatriptan 130
and L-dopa 120 anaesthetics, dissociative 326 thrombin inhibitors 374
and G.a downregulation 414 analgesics 129, 265 arterioles 131, 257
and multifunctional signalling 241 anaphylaxis, lung 27 arthritis
mutants 304 androgens 61 and tachykinin receptors 82
and Parkinson's disease 34 androstanolone 61 aspartyl protease (HIV) 199
structure—function relationships 421 anergy 221 asthma
8-adrenoceptor kinase (BARK) 307 angiotensin II 345 and airway hyperreactivity
age annexins, see lipocortins 208, 275, 432 (L)
and neurotransmitter regulation 403 antagonists and airway wall remodelling 275
aggression antibodies as 388 and endothelins 30
and anabolic—androgenic steroids 63 definition of 270 and GABA, receptors 27
agonists of L-dopa binding site 120 immunopharmacology of 208
and constitutive activity of receptors 305 of excitatory amino acids 325 and leukotrienes 351
definition of 270 of mitochondrial Na*—Ca?+ exchanger 409 and tachykinin receptors 81
and G-protein regulation 413, 421 and receptor classification 376 astrocytes
and receptor classification 378 silent, of 5-HT,, receptors 441 and CNS injury 3°
(see also adenosine; cholecystokinin; of transforming growth factor B 341 atherosclerosis 157, 227
endothelin; G protein-coupled; GABA,; (see also adenosine; cholecystokinin; athletic performance
5-HT,; metabotropic glutamate; endothelin; GABA,; 5-HT,; 5-HT;; IL-1; and anabolic—androgenic steroids 62
muscarinic acetylcholine; NMDA; muscarinic acetylcholine; NMDA; atopy
8-opioid; and tachykinin receptors) 8-opioid; T cell and tachykinin receptors) and asthma 209
AIDS, see acquired immune deficiency antagonist equilibrium dissociation ATP receptors (P, purinoceptors) 50
syndrome constant (K,) 89, 111, 237, 296 (L) see adenosine A, receptors
airway hyperreactivity antibodies ATP synthesis
in asthma 208, 275, 432 (L) as antagonists 388 and Nat-Ca?* exchange 408
airway wall remodelling (see also monoclonal antibodies) aura
in asthma 276 anticatabolism 62 in headache 129
aldosterone 1 anticoagulation 366 autacoids 211
aldosterone receptors 1 anticonvulsants 23, 326 autoantigens 213
allergic disease 167, 209 antidepressants autoimmunity
allograft rejection 160 and 5-HT 262 (L), 263 (L), 396 (L), 397 (L), to glutamate decarboxylase 108
allosteric ternary complex model 306 398 (L) and immunological tolerance 143
and immunosuppression 178, 213 vaccines 202 89, 110, 237
and immunotoxins 148 capillaries 257 effects of ‘rogue’ points 399
role of interleukins 155, 161 carbachol 415 convergent combination therapy
autonomic failure 349 carbonic anhydrase and AIDS 201
autoreceptors 259, 442 and structur—based drug design 19] Cori cycle 115
aversion 5-carboxamidotryptamine (5-CT) 229 coronary arteries 448
and 5-HT; receptor antagonists 266 cardiac tissue corticotrophin-releasing factor 317
axon growth and adenosine receptors 362 cough 28
after injury 341 adenylyl cyclase in 34 coumarins 367
azathioprine 214 carnitine and derivatives 355 Coxsackievirus 108
and ischaemia 448 CP96345 81, 315, 380
B cells mechanisms in 257 CP99994 81, 315
and immunointervention 213 mitochondria in 408 CREB (transcription factor) 438
B7 gene and Nat*-—Ca?* exchange 408 cromakalim 332
and cancer vaccines 205 and relaxin 4, 231 (L), 232 (L) cyclic AMP, cardiac 34
baclofen 27, 259, 391 ryanodine receptors in 99 cyclooxygenase (COX) enzymes 289
bacterial endotoxins 169 and thrombin 366 cyclophilin 161, 182, 193, 423
bacteriorhodopsin 8 cardiovascular diseases 41, 63, 227 cyclophosphamide 214
basic fibroblast growth factor 337 carnitine 355 cytoplasmic hormone receptors, see
bemesetron 265 carnitine acyltransferases 355 immunophilins
benzodiazepines 77 (BR), 406 catecholamine receptors 9 cytochromes P450 (CYP system)
2, 3-benzodiazepines 325 CD3 monoclonal antibody 213 drug metabolizing enzyme 292
benzodiazepine receptors CD4 monoclonal antibody 213 cytokines
and cholecystokinin 248 CD4/CD8 monoclonal antibody 143 as adjuvants 176
Blaschko, Hermann (Obituary) 264 CD4* T cells and asthma 209
blood-brain barrier 313 (BR) activation by adjuvants 175 and cancer vaccines 206
blood flow blockade 180 and HIV infection 197
cerebral 130, 247, 285 (BR) and HIV binding 196 immunotherapy 155, 159, 164
and myocardial ischaemia 448 regulation by cytokines 164 and inflammation 289
blood pressure 4, 59, 349 CD8* T cells inhibition by steroids 438
blood vessels and immunostimulating complexes 175 and multiple sclerosis 124
see arteries, arterioles, capillaries and veins CD28 and T cells 144, 164
bombesin receptors 316 and T-cell activation 205 and wounding response 338
bone disease 319 cell death 37, 196, 337 cytoskeleton
bone marrow, transplantation 218 cell growth and exocytosis 347
boronic acid derivatives 370 and lysophosphatidic acid 249 cytosolic proteins
BQ123 57 cell-mediated immunity 164, 210 and exocytosis 347
bradykinin 287 cell migration 217, 249
bradykinin receptors 288, 382 cerebral blood flow 130, 247, 285 (BR) DALCE 84
brain CGP35348 259, 391 decorin 341
and relaxin 4 CGP52432 259, 391 dendritic cells
brain disorders 77 (BR) CGRP, see calcitonin gene-related peptide and antigens 220
brainstem nuclei Cheng-Prusoff equation depression
and cholecystokinin 246 89, 110, 237, 294 (L), 295 (L), 296 (L) and anabolic—androgenic steroids 67
bromocriptine 127 chimaeras and corticotropin-releasing factor 317
bronchospasm 26, 30, 275 antibody 139 and endothelins 59
buspirone 445 immunotoxins 148, 162 and GABA, receptor antagonists 393
in transplantation 217 and 5-HT,, receptors 447
Ca?+ chirality desensitization, receptor 279, 413
and adenylyl cyclase, cardiac 34 in drug action 68 devazepide 245
in bone biology 319 cholecystokinin 244 dextromethorphan 327
and L-dopa release 119 cholecystokinin receptors 244, 382 dextrorphan 327
and endothelins 31, 54 cholera toxin 416 1,2-diacyclglycerol (DAG) 279
and exocytosis 348 cholesterol diadenosine polyphosphates 348
and IP, 78 (BR), 86 and anabolic—androgenic steroids 63 diazepam 329
and K* channel openers 333 cholinergic neurones, airway 26 dideoxynucleosides
and lysophosphatidic acid 250 chromaffin cells 52, 345 and AIDS therapy 196
and mitochondria, heart 408 chromogranins 345 D-cis-diltiazem 409
and NMDA receptors 297 C1988 245 diphtheria toxin 150, 163
and P, purinoceptors 52 ciclosporin dizocilpine 327
and receptor desensitization 283 anti-asthma therapy 208 DNA aptamers
and ryanodine receptors 98 and endothelins 60 and thrombin inhibition 372
and T-cell receptors 182 immunosuppression by 161, 182, 192, 213 donor-recipient interaction
Ca?* channels 17, 88, 98 interaction with receptor 423 in transplantation 217
Ca?*—calmodulin-dependent kinase II clonazepam 409 L-dopa 119
(CaM kinase II) 88, 99 clomipramine 262 (L), 263 (L) dopamine 33, 119
caffeine 100, 454 (BR) CNS injury 337 dopamine receptors 43
calcineurin 161, 182, 193 co-agonists dopamine transporter 43
calcitonin 113, 319 at NMDA receptor 20 DPDPE 84
calcitonin gene-related peptide (CGRP) coagulation drug abuse 61, 247, 268
113, 287, 319 and thrombin 367 drug design
calmodulin 34, 183 cocaine 47 to macromolecular targets 135 (BR)
CaM kinase II (Ca2*—calmodulin- cognition 269, 392 phospholipase A, inhibitors 96
dependent kinase II) 88, 99 complementary determining regions structure-based 189
cancer (CDRs) targeted to nucleic acid 385 (BR)
and endothelins 60 in humanized antibodies 140 thrombin inhibitors 369
and IL-2 therapy 160 composite chiral drugs 68 drug metabolism
and immunostimulants 169 computer analysis prediction in humans 292
and immunotoxins 148 and ‘rogue’ points 399 drug potency 270
and ochratoxin A 424 concentration—effect curves drug resistance
and thrombin 367 and antagonist affinity constants and autoimmunity 215
DSLET 84 glucose intolerance 113 IL-1 receptors 155
glutamate 20, 259 IL-1 receptor antagonist (IL-1Ra) 155
Enantiomers glutamate decarboxylase 107 IL-2 receptor 159, 438
in drug action 69 glutamate receptors, see ionotropic and image analysis 319
endoplasmic reticulum 86 metabotropic glutamate receptors immune system 124, 137, 287
endothelial cells 366, 449 glycine immunoglobulin E 208
endothelins 29, 54, 225, 452 site, NMDA receptor 20 immunopharmacology 137
endothelin receptors 29, 54, 225 GR100679 82 immunophilins 182, 193, 423
enkephalins 345 GR103537 82 immunostimulants 169
enzymes GR159897 315 immunostimulating complexes
inhibition, and drug design 182, 366 graft-versus-host disease 162, 218 and CD8* T cells 175
isoforms, and drug metabolism 293 granisetron 266 immunosuppression
eosinophils 277 growth factors 149, 277, 338 agents 161, 182
epilepsy, see seizures GYKI52466 330 and autoimmune diseases 213
epithelium and monoclonal antibodies 143
damage in asthma 276 H*/K*-transporting ATPase selective 178
ergot alkaloids 130 inhibitors 323 and structure-based drug design 189
eudismic analysis HA966 22 and organ transplantation 217
of chiral drugs 70 headache immunotherapy
excitatory amino acid receptors in migraine 129 antibody-based 139, 143, 148
134 (BR), 325, 387 health 134 (BR), 424, 454 (BR) clinical perspectives
exocytosis 345 heart, see cardiac tissue 196, 202, 208, 213, 217
experimental allergic encephalomyelitis helical wheel projection model cytokine-based 155, 159, 164
(EAE) 124, 167, 179 (muscarinic acetylcholine receptor) 309 by immunomodulation
heparins 278, 367 169, 174, 178, 182, 189
Fatty acid metabolism 355 herbal drugs 75 (BR), 169 for multiple sclerosis 124
FK506 (immunosuppressor) Hill equation 399 immunotoxins 148, 162
161, 182, 192, 423 hippocampus imreg 172
FK224 81 metabotropic glutamate receptors in 18 infectious disease
FK888 81 hirudin 372 and CD4* T cells 167
FK506-binding protein 161, 182, 193 hirulog 372 ‘infectious’ tolerance 145
focal adhesion kinase (p125*4) 252 histamine 209, 275 inflammation
free radicals 36, 358, 450 HIV, see human immunodeficiency virus and asthma 209, 275
Freund’s complete adjuvant 175 HIV life cycle and CD4* T cells 167
fungal glycans 169 and therapeutic intervention 198 and cyclooxygenase enzymes 289
fungal toxins 424 homochiral drugs 68 and endothelins 59
homologous competition assays 295 (L) and hyperalgesia 287
G proteins homology screening and IL-1 156
and multifunctional signalling 239, 273 and orphan receptors 394 and leukotrienes 351
and phosphoinositidase C signalling 280 hormone secretion 345 in migraine 132
regulation by agonists 413, 421 hormone therapy in multiple sclerosis 124
regulation of phospholipase A, 94 in experimental allergic and phospholipase A, enzymes 92
and synoptic receptor function 431 (L) encephalomyelitis 126 and steroids 436
G 416 host-graft interaction and thrombin 366
G,/G), 415 in transplantation 217 inhibition curves 89, 110, 237
G, 414, 421 5-HT inhibitory probes
G protein-coupled receptors and antidepressants 262 (L), 263 (L), to predict drug metabolism 293
constitutive activity of 303 396 (L), 397 (L), 398 (L) inositol 1,4,5-trisphosphate (IP)
endothelin receptors 54 and cholecystokinin 248 and Ca?* signalling 78 (BR), 279, 319
for lysophosphatidic acid 252 and inflammation 287 and endothelin receptors 54
metabotropic glutamate receptors 13 5-HT receptors and K+ channel openers 334
molecular modelling of 7 nomenclature 233 insulin 114
multifunctional signalling by 239 5-HT (serotonin) reuptake inhibitors insulin-dependent diabetes mellitus
muscarinic acetylcholine receptors 308 (SSRIs) 262 (L), 263 (L), 396 (L), 397 (L), (IDDM)
orphan receptors 394 398 (L) amylin deficiency in 117
GABA 248, 265 5-HT transporter 44 and CD4* T cells 167
GABA transporter 44 5-HT, receptors and glutamate decarboxylase
GABA, receptors 403, 422 heterogeneity of 228, 233 autoimmunity 108
GABAsg receptors 26, 259, 391 5-HT,, receptors immunosuppression in 213
Gaddum equation 237, 296 (L) agonist potency 271 and Na*—Ca** exchange in
galanin receptors 316 antagonists 262 (L), 263 (L), 441 mitochondria 412
gastric lesions and sumatriptan 132 and orthostatic hypotension 349
and endothelins 59 5-HT), receptor 381 insulin-like growth factor (IGF-1) 318
gastrin 323 5-HT jpg receptors 381 insulinoma amyloid peptide, see amylin
gene expression 5-HT, receptors interferons
and glucocorticoid receptors 437 antagonists 265 as adjuvants 176
relaxin 4 human immunodeficiency virus and CD4* T cell differentiation 165
ryanodine receptors 98 (HIV) 171, 196 inducers 173
Gilles de la Tourette syndrome 48 humoral immunity 164 and multiple sclerosis 124
glibenclamide 333 hydrogen peroxide 36 interleukins
gliosis hydroxyl radical (OH*) 37 general 155, 289, 438
and CNS injury 337 hyperalgesia interleukin 1 (IL-1)
glucagon 113 and inflammation 287 as adjuvant 176
glucocorticoids hyperpolarization and inflammation 289
and asthma 211 and K* channel opening 332 inhibition by steroids 438
and inflammation 436 hypoglycaemia 117 reducing its activity in disease 155
and lipocortins 95 hypoxia 225, 356 interleukin 2 (IL-2) 159, 176, 182
and multiple sclerosis 125 interleukin 4 (IL-4) 165, 438
glucocorticoid receptor 436 Idazoxan 33 inward rectification 322
glucocorticoid response elements idiotype vaccination 207 ion channels
(GREs) 437 IL-1, see interleukin 1 general 385 (BR)
modulation by glutamate receptors 17 memantine 329 NF-AT (nuclear factor of activated T cells)
nomenclature 433, 435 membrane proteins 182, 439
ionotropic glutamate receptors of chromaffin granules 346 NF,B (transcription factor) 438
297, 387, 428 metabolism 113, 292 nicorandil 332
IP, see inositol 1,4,5-trisphosphate metatropic glutamate receptors 13, 18, 387 nicotinic acetylcholine receptor 421
IP; receptor 86, 284, 319 methotrexate 214 nitric oxide, see NO
ischaemia a-methyl-4-carboxy-phenylglycine nitric oxide synthase 439
and carnitine 355 (MCPG) 389 nitrovasodilators 40
and endothelins 59 microbes NK, receptor
and excitatory amino acid immunostimulant source 169 antagonists 81,315
antagonists 325 microvascular leakage, airway 26 species homologues 380
myocardial 412, 448 migraine 129, 265 structure-function relationships 421
‘isomeric ballast’ mineralocorticoids l NK, receptors 81, 315, 376
in composite chiral drugs 69 mineralocorticoid receptors l NK, receptors 376
isomerization mitochondrial metabolism 36, 408 NMDA receptors
of receptors 303 modelling antagonists 325
isoprenaline 414 bacteriorhodopsin 8 glycine site, antagonists 20
in drug design 189, 369 invertebrate 430
K* channels of G protein-coupled receptors 7 modulation by glutamate receptors 17
and anti-asthma therapy 210 humanized antibodies 140 molecular biology of 297, 387
ATP-activated 322, 332 muscarinic acetylcholine receptors 309 NO (nitric oxide)
inwardly rectifying, core 320 phospholipase A, 96 and bone biology 320
modulators 17, 255 (BR) in toxicology 254 (BR) and endothelins 227
nomenclature 433, 434, 435 molecular mimicry as free radical scavenger 39
openers 332 in autoimmunity 108 and myocardial ischaemia 449
and P, purinoceptors 52 monoamine oxidase B inhibitors 384 (BR) nociception
Shaker 320 monoclonal antibodies and neuropeptides 317
K,, (antagonist equilibrium dissociation humanized 139 nonchiral drugs 68
constant) 89, 111, 237, 296 (L) to IL-2 receptor 162 non-insulin-dependent diabetes mellitus
kainate receptors and immunological tolerance 143 (NIDDM) 118
antagonists 329 in immunosuppression 178, 213 non-ionic block polymer (NBP)
invertebrate 429 in immunotoxins 149 surfactants 175
molecular biology of 297, 387 radiolabelled 163 noradrenaline
kynurenic acid 22 morphine 84, 267 and cholecystokinin 248
MPTP 33, 48 and L-dopa release 119
L365260 245 multifunctional drugs 70 and orthostatic hypotension 349
‘lead’ inhibitor molecule multiple sclerosis 124, 167, 180 and Parkinson’s disease 33
in drug design 189 multiple system atrophy 349 and vasoconstriction 452
leishmaniasis muramyl dipeptides 169, 176 noradrenaline transporter 44
and CD4* T cells 167 muscarinic acetylcholine receptors nuclear factor of activated T cells
leucine zipper agonist binding site 9 (NF-AT) 182, 439
in transporter proteins 46 desensitization 280 nuclear hormone receptors 423
leukemia, acute and chronic myelogenous and G-protein coupling 415, 421 nuclear magnetic resonance (NMR) 189
157, 162 molecular biology of 308
leukocytes 1, 218, 432 (L) subtypes 377 Obesity
leukotrienes 351 muscle 62, 99, 428 and amylin 113
leukotriene A, 351 (see also smooth muscle) ochratoxin A 424
levodopa 119 myocardial ischaemia 412, 448
oncogenes
ligand identification (‘reverse as tumour antigens 203
pharmacology’ ) 394 Nat ondansetron 266
lipid A analogues 170, 176 and P, purinoceptors 51 5 opioid receptors 84
lipids 92, 355, 439 Na*-Ca?* exchanger (mitochondria) 408 optical probes 456 (BR)
lipocortins (annexins) 95, 125, 439 Na*—H* exchanger orphan receptors 394
lipoxins 351 and aldosterone 1 orthostatic hypotension 349
liver 114, 217 Na*/K*+-ATPase 1, 47 osteoblasts 319
liver disorders natural killer cells 169 osteoporosis 319
and anabolic—androgenic steroids 63 natural products oxidant stress 36, 356
long-term depression (LTD) 389 as drugs 455 (BR) oxygen
long-term potentiation (LTP) 19, 390 nausea 265 and headache 132
LTD (long-term depression) 389 NBQX 329
LTP (long-term potentiation) 19, 390 NECA 361 P, purinoceptors (ATP receptors) pain 50
lung 26, 29 nerve growth factor (NGF) 289, 318 and 5-HT, receptors 265
lymphatics 257 neurodegenerative diseases and inflammation 287
lymphokines, see cytokines and thrombin 366 and neuropeptides 317
lysophosphatidic acid 249 (see also named diseases) and tachykinin receptors 81
lysophosphatidic acid receptor 251 neurones pancreatic B cells 113
and glutamate receptors, panic attacks
Macrophages 124, 169, 337 invertebrate 429 and cholecystokinin 244, 317
major histocompatibility complex (MHC) and P, purinoceptors 50 and 5-HT receptors 267, 445
and antigen recognition 143 and thrombin 367 parathyroid hormone 319
binding of peptides 178 neuropeptides 287, 315 parking experiments
blockade 179 neuropeptide receptors 315 in transplantation 221
and cancer vaccines 205 neurotensin receptor 316 Parkinson’s disease
manoalide neurotransmitters dopamine transporter in 48
phospholipase A, inhibition 95 receptors 9, 403 and NMDA receptor antagonists 328
mast cells release 387, 391 noradrenergic mechanisms in 33
and asthma 278 transporters 43 and orthostatic hypotension 349
MCPG (a-methyl-4-carboxy- (see also named neurotransmitters) partial agonism
phenylglycine) 389 neurotrophic factors 318, 339 definition 270
melanoma-specific gene product neutrophils 41, 449 at 5-HT,, receptors 441
(MAGE1) 203 nexin 426 and hormone-receptor models 10